Diffuse Large B Cell Lymphoma Clinical Trials in Salt Lake City, Utah

4 studies are recruiting for diffuse large b cell lymphoma in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

    Stage
    Phase 1
    Ages
    0 to 25
    Site
    Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah
    Locations
    71 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06395103 on ClinicalTrials.gov

  2. Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

    This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will utilize a staggered …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT06227026 on ClinicalTrials.gov

  3. External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

    The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT07528352 on ClinicalTrials.gov

  4. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

    This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
    Locations
    4 in total
    Run by
    Newave Pharmaceutical Inc

    See if you can join NCT04775745 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.